RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy

Prostate

Volumn 72, Issue 10, 2012, Pages 1071-1079

  Kawata, Hirotoshi ^a   Shimada, Naoki ^a,c   Kamiakito, Tomoko ^a   Komatsu, Kenji ^a   Morita, Tatsuo ^a   Ota, Toshio ^b   Obayashi, Masaya ^b   Shitara, Kenya ^b   Tanaka, Akira ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

endocrine resistance; prostate cancer; Rho GTPase

Indexed keywords

ACTIN; ACTIVIN; ANDROGEN; ANTIANDROGEN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INHIBIN; MEMBRANE PROTEIN; NERVE CELL ADHESION MOLECULE; OLIGONUCLEOTIDE; PHALLOIDIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN NET1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CARCINOMA CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE MICROSCOPY; GLEASON SCORE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS FIBER; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MIDDLE AGED; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; RHO GTP-BINDING PROTEINS; TIME FACTORS;

EID: 84861577377     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21511     Document Type: Article

References (36)

1. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
2. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK,. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002; 23: 967-975.
3. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP,. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999; 91: 1758-1764.
4. Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A,. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003; 129: 662-668.
5. Pfundt R, Smit F, Jansen C, Aalders T, Straatman H, van der Vliet W, Isaacs J, van Kessel AG, Schalken J,. Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. Genes Chromosomes Cancer 2005; 43: 273-283.
6. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K,. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci 1992; 89: 8928-8932.
7. Tanaka A, Miyamoto K, Matsuo H, Matsumoto K, Yoshida H,. Human androgen-induced growth factor in prostate and breast cancer cells: Its molecular cloning and growth properties. FEBS Lett 1995; 363: 226-230.
8. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M,. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998; 58: 2053-2056.
9. Tanaka A, Kamiakito T, Takayashiki N, Sakurai S, Saito K,. Fibroblast growth factor 8 expression in breast carcinoma: Associations with androgen receptor and prostate-specific antigen expressions. Virchows Arch 2002; 441: 380-384.
10. Heasman SJ, Ridley AJ,. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.
11. Bos JL, Rehmann H, Wittinghofer A,. GEFs and GAPs: Critical elements in the control of small G proteins. Cell 2007; 129: 865-877.
12. Sahai E, Marshall CJ,. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2: 133-142.
13. Labouesse M,. Epithelium-mesenchyme: A balancing act of RhoGAP and RhoGEF. Curr Biol 2004; 14: R508-R510.
14. Thiery JP, Acloque H, Huang RY, Nieto MA,. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
15. Tanaka A, Hasegawa Y, Hakamata Y, Kamiakito T, Kuriki K, Yoshida H, Fukayama M,. Purification of activins from androgen-independent Shionogi carcinoma cells demonstrates enhanced expression of activin betaB-subunit under androgen-depleted cell conditions in vitro and in vivo. J Cell Physiol 2001; 188: 194-200.
16. Schmidt A, Hall A,. The Rho exchange factor Net1 is regulated by nuclear sequestration. J Biol Chem 2002; 277: 14581-14588.
17. Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V, Palacios J, Portillo F, Cano A,. The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc 2009; 4: 1591-1613.
18. Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P,. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 2006; 66: 2188-2194.
19. Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, Härkönen P,. FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 2008; 123: 22-31.
20. Shimada N, Ishii T, Imada T, Takaba K, Sasaki Y, Maruyama-Takahashi K, Maekawa-Tokuda Y, Kusaka H, Akinaga S, Tanaka A, Shitara K,. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo. Clin Cancer Res 2005; 11: 3897-3904.
21. Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A, Shitara K,. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 2008; 68: 640-650.
22. Clark EA, Golub TR, Lander ES, Hynes RO,. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
23. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, Mak TW,. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005; 19: 1974-1979.
24. Shikada Y, Yoshino I, Okamoto T, Fukuyama S, Kameyama T, Maehara Y,. Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clin Cancer Res 2003; 9: 5282-5286.
25. Yao H, Dashner EJ, van Golen CM, van Golen KL,. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2006; 25: 2285-2296.
26. Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Furuta E, Liu W, Xing F, Okuda H, Kobayashi A, Watabe K,. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008; 68: 7613-7620.
27. Murray D, Horgan G, Macmathuna P, Doran P,. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br J Cancer 2008; 99: 1322-1329.
28. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM,. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006; 25: 6959-6967.
29. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI,. Tamoxifen resistance in MCF7cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006; 118: 290-301.
30. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC,. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci 2009; 106: 13820-13825.
31. Christiansen JJ, Rajasekaran AK,. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
32. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA,. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13: 7003-7011.
33. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S,. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006; 20: 2315-2325.
34. Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE,. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 2007; 14: 245-256.
35. Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, Yamada T, Kamoto T, Ogawa O, Nakamura E,. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. Mol Endocrinol 2010; 24: 722-734.
36. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL,. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 2008; 22: 597-608.